Tositumomab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD20 |
Clinical data | |
Trade names | Bexxar |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609013 |
ATC code | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6416H9874N1688O1987S44 |
Molar mass | 143860.04 g·mol−1 |
(what is this?) (verify) |
Tositumomab is a
The drug combination was developed by
Clinical use
A personalized regimen using Bexxar was approved for the treatment of relapsed or
The radioactive dose was adjusted for each patient in order to maximize the radiation delivered to the tumor and minimize the exposure of other organs.
Availability
United States
Following a first
Europe
The
References
- ^ a b c d e "BEXXAR drug label" (PDF). FDA. GlaxoSmithKline. August 2012. Retrieved 18 January 2016.
- ^ "Guide to Antibody structure and isotypes". Abcam. Retrieved 25 July 2020.
- ^ Mozee, Carla (29 April 2005). "Glaxo to acquire Corixa for $300 million". MarketWatch.
- ^ PMID 21436340.
- ^ PMID 17530015.
- ^ a b Timmerman, Luke (26 August 2013). "Why Good Drugs Sometimes Fail: The Bexxar Story". Xconomy.
- ISSN 0362-4331.New York Times. July 1, 2003 Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval
- ^ a b "Tositumomab - Product Approval Information - Licensing Action". FDA/Center for Drug Evaluation and Research. 2 July 2003.
- ^ a b c "Tositumomab product description". Food and Drug Administration. Archived from the original on 27 January 2018. Retrieved 25 July 2020.
- ^ "Briefing Information Iodine I-131 Tositumomab". Food and Drug Administration. 17 December 2002. Archived from the original on 25 January 2018. Retrieved 25 July 2020.
- ^ "GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR". Federal Register. 23 October 2013. (78 FR 63226)
- ^ "EU/3/03/137". European Medicines Agency. 17 September 2018. Retrieved 25 July 2020.
- ^ "EU/3/03/136". European Medicines Agency. 17 September 2018. Retrieved 25 July 2020.